Immune Pharmaceuticals Stock Revenue
Immune Pharmaceuticals fundamentals help investors to digest information that contributes to Immune Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Immune OTC Stock. The fundamental analysis module provides a way to measure Immune Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immune Pharmaceuticals otc stock.
Immune |
Immune Pharmaceuticals OTC Stock Revenue Analysis
Immune Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Immune Pharmaceuticals Revenue | 19 K |
Most of Immune Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Immune Pharmaceuticals reported 19 K of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Major industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Immune Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Immune Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Immune Pharmaceuticals by comparing valuation metrics of similar companies.Immune Pharmaceuticals is currently under evaluation in revenue category among related companies.
Immune Fundamentals
| Return On Asset | -42.63 | |||
| Current Valuation | 8.67 M | |||
| Shares Outstanding | 72.38 M | |||
| Shares Owned By Insiders | 2.16 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | (0.17) X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 858.11 X | |||
| Revenue | 19 K | |||
| EBITDA | (13.77 M) | |||
| Net Income | (34.39 M) | |||
| Cash And Equivalents | 76 K | |||
| Total Debt | 8.33 M | |||
| Debt To Equity | 989.50 % | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (14.69 M) | |||
| Short Ratio | 1.32 X | |||
| Earnings Per Share | (1.15) X | |||
| Beta | 2.99 | |||
| Market Capitalization | 553.21 K | |||
| Total Asset | 36.18 M | |||
| Retained Earnings | (62.99 M) | |||
| Working Capital | (1.45 M) | |||
| Current Asset | 4.83 M | |||
| Current Liabilities | 6.29 M | |||
| Z Score | -1.4 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Immune OTC Stock
If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |